Immunosuppressive or surgical treatment for ocular myasthenia gravis

Archives of Neurology

Volumn 64, Issue 12, 2007, Pages 1792-1794

  Chavis, Pamela S ^a,b   Stickler, David E ^a   Walker, Aljoeson ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ARTICLE; AUTOIMMUNE DISEASE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; ELECTROMYOGRAPHY; EYE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LOW DRUG DOSE; MONOTHERAPY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REMISSION; RISK BENEFIT ANALYSIS; THYMECTOMY; THYMOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EYE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; PREDNISONE; THYMECTOMY;

EID: 37149011857     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.12.1792     Document Type: Article

References (22)

1. Blalock A. Thymectomy in the treatment of myasthenia gravis: report of 20 cases. J Thorac Surg. 1944;13:316-339.
2. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62(2):156-162.
3. Tackenberg B, Hemmer B, Oertel WH, Sommer N. Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs. 2001;15(6):369-378.
4. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting the outcome. Ann N Y Acad Sci. 1987;505:472-499.
5. Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol. 2000;111 (7):1203-1207.
6. Weinberg DH, Rizzo JF III, Hayes MT, Kneeland MD, Kelly JJ Jr. Ocular myasthenia gravis: predictive values of single-fiber electromyography. Muscle Nerve. 1999;22(9):1222-1227.
7. Mantegazza R, Beghi E, Pareyson D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol. 1990;237(6):339-344.
8. Evoli A, Tonali P, Bartoccioni E, LoMonaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988;77(1):31-35.
9. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, and modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526-538.
10. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at The Hospital for Sick Children. Ophthalmology. 2000;107(3):504-510.
11. Mantegazza R, Baggi F, Antozzi L, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci. 2003;998:413-423.
12. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131-133.
13. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243-248.
14. Komiyama A, Arai H, Kijama M, Hirayama K. Extraocular muscle responses to high dose intravenous ethylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2000;68(2):214-217.
15. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235(8):449-453.
16. Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59-62.
17. Wakata N, Iguchi H, Sugimoto H, Nomoto N, Kurihara T. Relapse of ocular symptoms after remission of myasthenia gravis: a comparison of relapsed and complete remission cases. Clin Neurol Neurosurg. 2003;105(2):75-77.
18. Huang C-S, Hsu H-S, Huang B-S, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand. 2005;112(2):108-114.
19. Schumm F, Wiethölter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985;48(4):332-337.
20. Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122(3):562-568.
21. Wagner AJ, Cortes RA, Strober J, et al. Longterm follow-up after thymectomy for myasthenia gravis: thorascopic vs open. J Pediatr Surg. 2006;41(1):50-54.
22. Halnon NJ, Jamieson B, Plunkett M, Kitchen CM, Pham T, Krogstad P. Thymic function and impaired maintenance of peripheral T cell populations in children with congenital heart disease and surgical thymectomy. Pediatr Res. 2005;57(1):42-48.